{
  "nodes": [
    {
      "id": "node_001",
      "content": "EGFR exon 19 deletion or exon 21 L858R mutations",
      "parent_ids": [],
      "children_ids": [
        "node_002",
        "node_003"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "nn"
      ]
    },
    {
      "id": "node_002",
      "content": "EGFR mutation discovered prior to first-line systemic therapy",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_004",
        "node_005",
        "node_006",
        "node_007"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_003",
      "content": "EGFR mutation discovered during first-line systemic therapy",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_008",
        "node_009",
        "node_010"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_004",
      "content": "Preferred: Osimertinib (category 1)",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_011"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "rr",
        "ss"
      ]
    },
    {
      "id": "node_005",
      "content": "Other Recommended: Amivantamab-vmjw + lazertinib (category 1)",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_012"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "rr",
        "tt"
      ]
    },
    {
      "id": "node_006",
      "content": "Other Recommended: Osimertinib + pemetrexed + (cisplatin or carboplatin) (nonsquamous) (category 1)",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_013"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "rr"
      ]
    },
    {
      "id": "node_007",
      "content": "Useful in Certain Circumstances: Afatinib (category 1) or Dacomitinib (category 1) or Erlotinib (category 1) or Erlotinib + bevacizumab or Erlotinib + ramucirumab or Gefitinib (category 1)",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_014"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "rr",
        "ss",
        "uu",
        "vv"
      ]
    },
    {
      "id": "node_008",
      "content": "Add osimertinib to pemetrexed + (cisplatin or carboplatin) (nonsquamous)",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_015"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "rr"
      ]
    },
    {
      "id": "node_009",
      "content": "Interrupt current therapy and start Osimertinib or Amivantamab-vmjw + lazertinib",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_016"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "rr",
        "tt",
        "ww",
        "xx"
      ]
    },
    {
      "id": "node_010",
      "content": "or Afatinib or Dacomitinib or Erlotinib or Erlotinib + bevacizumab or Erlotinib + ramucirumab or Gefitinib",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_017"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "rr",
        "uu",
        "vv"
      ]
    },
    {
      "id": "node_011",
      "content": "Progression",
      "parent_ids": [
        "node_004"
      ],
      "children_ids": [
        "node_018"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_012",
      "content": "Progression",
      "parent_ids": [
        "node_005"
      ],
      "children_ids": [
        "node_019"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_013",
      "content": "Progression",
      "parent_ids": [
        "node_006"
      ],
      "children_ids": [
        "node_020"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_014",
      "content": "Progression",
      "parent_ids": [
        "node_007"
      ],
      "children_ids": [
        "node_021"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_015",
      "content": "Progression",
      "parent_ids": [
        "node_008"
      ],
      "children_ids": [
        "node_022"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_016",
      "content": "Progression",
      "parent_ids": [
        "node_009"
      ],
      "children_ids": [
        "node_023"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_017",
      "content": "Progression",
      "parent_ids": [
        "node_010"
      ],
      "children_ids": [
        "node_024"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_018",
      "content": "Subsequent Therapy",
      "parent_ids": [
        "node_011"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-22"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_019",
      "content": "Subsequent Therapy",
      "parent_ids": [
        "node_012"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-22"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_020",
      "content": "Systemic Therapy, Subsequent",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 4 of 5"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_021",
      "content": "Subsequent Therapy",
      "parent_ids": [
        "node_014"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-23"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_022",
      "content": "Systemic Therapy, Subsequent",
      "parent_ids": [
        "node_015"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 4 of 5"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_023",
      "content": "Subsequent Therapy",
      "parent_ids": [
        "node_016"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-22"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_024",
      "content": "Subsequent Therapy",
      "parent_ids": [
        "node_017"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-23"
      ],
      "footnote_labels": []
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-21",
      "to_tree": "NSCL-22",
      "description": "Subsequent Therapy pathway following progression on Osimertinib or Amivantamab/Lazertinib"
    },
    {
      "from_tree": "NSCL-21",
      "to_tree": "NSCL-K 4 of 5",
      "description": "Systemic Therapy, Subsequent pathway following progression on Osimertinib + Pemetrexed + Chemo"
    },
    {
      "from_tree": "NSCL-21",
      "to_tree": "NSCL-23",
      "description": "Subsequent Therapy pathway following progression on other EGFR inhibitors (Afatinib, Erlotinib, etc.)"
    },
    {
      "from_tree": "NSCL-21",
      "to_tree": "NSCL-H",
      "description": "Principles of Molecular and Biomarker Analysis"
    },
    {
      "from_tree": "NSCL-21",
      "to_tree": "NSCL-J",
      "description": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease"
    }
  ],
  "footnotes": [
    {
      "label": "nn",
      "content": "Principles of Molecular and Biomarker Analysis (NSCL-H)."
    },
    {
      "label": "rr",
      "content": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J)."
    },
    {
      "label": "ss",
      "content": "For performance status (PS) 0\u20134."
    },
    {
      "label": "tt",
      "content": "Prophylactic anticoagulation is recommended at the time of initiation to prevent venous thromboembolic events."
    },
    {
      "label": "uu",
      "content": "Criteria for treatment with bevacizumab: nonsquamous NSCLC, and no recent history of hemoptysis."
    },
    {
      "label": "vv",
      "content": "An FDA-approved biosimilar is an appropriate substitute for bevacizumab."
    },
    {
      "label": "ww",
      "content": "If systemic therapy regimen contains an immune checkpoint inhibitor, physicians should be aware of the long half-life of such drugs and data reporting adverse events when using osimertinib in combination with or following checkpoint inhibitors. The rate of side effects (pneumonitis) is higher within 3 months. Schoenfeld AJ, et al. Ann Oncol 2019;30:839-844; Oshima Y, et al. JAMA Oncol 2018;4:1112-1115; Oxnard GR, et al. Ann Oncol 2020;31:507-516; Gettinger S, et al. J Thorac Oncol 2018;13:1363-1372."
    },
    {
      "label": "xx",
      "content": "If there is a good response to current therapy, it is reasonable to continue therapy."
    }
  ],
  "extraction_confidence": 0.95,
  "image_title": "EGFR EXON 19 DELETION OR EXON 21 L858R MUTATIONS",
  "tree_id": "NSCL-21"
}